Strategic Blueprint’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $741K | Sell |
30,778
-2,407
| -7% | -$63K | 0.04% | 363 |
|
|
2026
Q1 | $932K | Sell |
33,185
-128
| -0.4% | -$3.41K | 0.05% | 291 |
|
|
2025
Q4 | $829K | Sell |
33,313
-3,426
| -9% | -$86.4K | 0.05% | 304 |
|
|
2025
Q3 | $936K | Sell |
36,739
-2,091
| -5% | -$51.6K | 0.04% | 347 |
|
|
2025
Q2 | $941K | Sell |
38,830
-6,169
| -14% | -$144K | 0.05% | 307 |
|
|
2025
Q1 | $1.14M | Sell |
44,999
-2,170
| -5% | -$56.8K | 0.06% | 262 |
|
|
2024
Q4 | $1.25M | Buy |
47,169
+942
| +2% | +$25.6K | 0.07% | 225 |
|
|
2024
Q3 | $1.34M | Sell |
46,227
-6,162
| -12% | -$180K | 0.08% | 205 |
|
|
2024
Q2 | $1.47M | Buy |
52,389
+1,715
| +3% | +$47.2K | 0.1% | 184 |
|
|
2024
Q1 | $1.41M | Buy |
50,674
+14,865
| +42% | +$412K | 0.1% | 189 |
|
|
2023
Q4 | $1.03M | Sell |
35,809
-9,556
| -21% | -$289K | 0.09% | 221 |
|
|
2023
Q3 | $1.5M | Buy |
45,365
+1,043
| +2% | +$36.9K | 0.14% | 151 |
|
|
2023
Q2 | $1.63M | Buy |
44,322
+1,715
| +4% | +$66.8K | 0.15% | 136 |
|
|
2023
Q1 | $1.74M | Sell |
42,607
-45,042
| -51% | -$1.95M | 0.18% | 130 |
|
|
2022
Q4 | $4.49M | Buy |
87,649
+50,855
| +138% | +$2.44M | 0.52% | 40 |
|
|
2022
Q3 | $1.61M | Buy |
36,794
+2,488
| +7% | +$121K | 0.19% | 126 |
|
|
2022
Q2 | $1.8M | Buy |
34,306
+1,718
| +5% | +$87.5K | 0.22% | 113 |
|
|
2022
Q1 | $1.69M | Buy |
32,588
+1,685
| +5% | +$87.4K | 0.2% | 111 |
|
|
2021
Q4 | $1.82M | Buy |
30,903
+2,803
| +10% | +$139K | 0.23% | 96 |
|
|
2021
Q3 | $1.21M | Buy |
28,100
+1,235
| +5% | +$54.7K | 0.19% | 117 |
|
|
2021
Q2 | $1.05M | Buy |
26,865
+1,776
| +7% | +$69.1K | 0.16% | 127 |
|
|
2021
Q1 | $909K | Buy |
25,089
+828
| +3% | +$29.4K | 0.19% | 112 |
|
|
2020
Q4 | $893K | Buy |
24,261
+4,643
| +24% | +$170K | 0.22% | 97 |
|
|
2020
Q3 | $683K | Buy |
19,618
+8,521
| +77% | +$299K | 0.21% | 94 |
|
|
2020
Q2 | $344K | Buy |
11,097
+133
| +1% | +$4.52K | 0.12% | 115 |
|
|
2020
Q1 | $340K | Buy |
10,964
+13
| +0.1% | +$443 | 0.2% | 81 |
|
|
2019
Q4 | $407K | Buy |
10,951
+8,614
| +369% | +$307K | 0.28% | 57 |
|
|
2019
Q3 | $80K | Sell |
2,337
-36,647
| -94% | -$1.33M | 0.06% | 122 |
|
|
2019
Q2 | $1.6M | Buy |
38,984
+2,385
| +7% | +$94.7K | 1.37% | 29 |
|
|
2019
Q1 | $1.48M | Buy |
36,599
+3,300
| +10% | +$132K | 1.34% | 27 |
|
|
2018
Q4 | $1.38M | Buy |
+33,299
| New | +$1.38M | 2% | 20 |
|
Other funds holding PFE
Strategic Blueprint's PFE Position: Q2 2026 in Review
Strategic Blueprint reduced its Pfizer (PFE) stake by 7.3% in Q2 2026, selling an estimated $63K and leaving 30,778 shares worth $741K. The position accounts for 0.04% of the portfolio, ranked #363.
Strategic Blueprint first reported a position in PFE in Q4 2018 and has held it in 31 quarters since. The position peaked at $4.49M in Q4 2022. 2,832 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Strategic Blueprint held 30,778 shares of Pfizer worth $741K as of Q2 2026.
- Strategic Blueprint sold 2,407 Pfizer shares in Q2 2026, an estimated $63K.
- Pfizer made up 0.04% of Strategic Blueprint's portfolio in Q2 2026, its #363 holding.
- Strategic Blueprint first reported a position in Pfizer in Q4 2018 and has held it in 31 quarters since.
- Strategic Blueprint's Pfizer position peaked at $4.49M in Q4 2022.
- 2,832 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Strategic Blueprint's 13F filing for Q2 2026, filed 23 Jul 2026.